Key Highlights

• Cerebras Systems (NASDAQ: CBRS) shares recovered sharply from a 52-week low of $160.81, gaining approximately 6% as Cathie Wood's ARK Investment Management accumulated $22.5 million worth of shares during the post-earnings selloff, signalling high-conviction belief in the wafer-scale inference thesis.

• All 10 Wall Street analysts covering the stock maintain Buy ratings with an average 12-month price target of $299.30, even as Q2 gross margin guidance of 36–38% triggered the initial selloff, creating a tug of war between AI infrastructure bulls and near-term margin bears.

Cerebras Systems (NASDAQ: CBRS) shares staged a meaningful recovery on Monday, gaining approximately 6% to reach $192.04 after touching a 52-week low of $160.81 just three sessions earlier — a level that proved irresistible for at least one high-profile institutional buyer.

Cathie Wood's ARK Investment Management disclosed a $22.5 million accumulation in Cerebras (CBRS) shares in the days following the earnings-driven selloff, signalling high-conviction belief in the company's wafer-scale inference architecture at prices that represented nearly a 50% discount to the stock's post-IPO highs. The move is consistent with ARK's historical strategy of buying aggressively into dislocations in transformative technology names.

The initial selloff was triggered by the company's Q1 2026 earnings report, which delivered strong headline numbers — revenue surged 92% year-over-year to $191.3 million, with cloud services and hardware both growing robustly — but included Q2 gross margin guidance of 36–38%, a significant compression from the 46.5% core gross margin reported in Q1. Shares fell approximately 10% in extended trading on the guidance disappointment, with selling accelerating over subsequent sessions before Monday's recovery.

Despite the margin concern, the unanimity of analyst support for Cerebras is striking. All 10 Wall Street analysts covering CBRS maintain Buy ratings, with zero sell recommendations and an average 12-month price target of $299.30 — implying roughly 55% upside from current levels. The Street-high estimate of $340 comes from Citi analyst Atif Malik, who initiated coverage with a Buy rating and argued the stock offers substantial upside given the structural demand tailwinds in AI compute.

Post-earnings, Morgan Stanley raised its price target to $273, UBS lifted its target to $320, and Wedbush bumped its estimate to $280 — all reaffirming their bullish stances despite the near-term margin headwind.

A supporting sector note from Citi highlighted that AI compute demand remains structurally undersupplied, with DRAM memory shortages identified as the single biggest constraint on available compute capacity — a dynamic that plays directly to Cerebras' differentiated wafer-scale inference architecture, which sidesteps many of the memory bandwidth bottlenecks that constrain conventional GPU-based inference systems.

Cerebras' core competitive claim against Nvidia (NASDAQ: NVDA) — its most formidable rival in the AI hardware market — centres on speed and cost advantages in inference workloads that arise from architectural differences between wafer-scale silicon and conventional GPU chip designs. This differentiation story continues to attract growth-oriented investors who believe the AI inference market will be large enough to sustain multiple hardware platforms.

Monday's recovery reflects a confluence of technical and fundamental forces: a stock that had declined nearly 50% from its post-IPO peak finding support near its 52-week low, unanimous analyst Buy consensus implying substantial upside, aggressive institutional accumulation by a high-profile investor, and a sector-wide AI infrastructure demand narrative that remains intact despite near-term margin volatility.